Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17451182 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL19283470 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL15876420 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL15876419 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL2525660 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL3755009 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL2525662 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL15728982 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL2525665 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL28720279 | 0.95 | CYP3A4 (0.79) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321275-B1 | CRYSTALLINE FORM OF SOFOSBUVIR | GILEAD SCIENCES INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3290428-B1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-105085592-B | N- [ (2' R) -2' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same | 吉利德制药有限责任公司 | 2021-04-27 | — | — | CN | disclosed |
| EP-3321275-A1 | CRYSTALLINE FORM OF SOFOSBUVIR | Gilead Pharmasset LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3290428-A1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | Gilead Pharmasset LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-2913337-B1 | PROCESS FOR THE PRODUCTION OF SOFOSBUVIR | GILEAD PHARMASSET LLC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9637512-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160354400-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. | 2016-12-08 | — | — | US | disclosed |
| US-8618076-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130310551-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-11-21 | — | — | US | disclosed |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-10-31 | — | — | US | disclosed |
| EP-2610264-A2 | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165644-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130078613-A1 | Selection of HCV Treatment | ROCHE MOLECULAR SYSTEMS (US) | 2013-03-28 | — | — | US | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165644-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3811/4885CYP2C9 3971/4885P2RY2 1380/4885 |
| US-20130310551-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3916/4885CYP2C9 4098/4885P2RY2 1271/4885 |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3811/4885CYP2C9 3971/4885P2RY2 1380/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3811/4885CYP2C9 3971/4885P2RY2 1380/4885 |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3811/4885CYP2C9 3971/4885P2RY2 1380/4885 |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3916/4885CYP2C9 4098/4885P2RY2 1271/4885 |
| US-20160354400-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3916/4885CYP2C9 4098/4885P2RY2 1271/4885 |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | CYP3A4 3811/4885CYP2C9 3971/4885P2RY2 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.